Inhibition of ACAT1 has received attention as a promising therapeutic target in AD and is believed to reduce amyloidogenic processing of APP by increasing the conversion of unesterified cholesterol to 24S-hydroxycholesterol39 by CYP46A150. This evidence concerns the gene ACAT1 and Alzheimer disease.